Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
OPERATING ACTIVITIES    
Net income $ 4,591 $ 1,412
Adjustments to reconcile net income to net cash provided by operating activities:    
Provision for doubtful accounts 102 (141)
Depreciation 9,236 8,335
Loss on disposal of and reserve adjustments for medical equipment 337 678
Gain on sale of medical equipment (2,282) (1,863)
Amortization of intangible assets 709 743
Amortization of deferred debt issuance costs 61 58
Stock-based compensation 3,091 3,276
Deferred income taxes 2,530 1,383
Changes in assets - (increase)/decrease:    
Accounts receivable (2,167) (1,348)
Inventories 941 (298)
Other current assets (762) 385
Other assets 1,028 1,137
Changes in liabilities - (decrease)/increase:    
Accounts payable and other liabilities (133) (1,229)
NET CASH PROVIDED BY OPERATING ACTIVITIES 17,282 12,528
INVESTING ACTIVITIES    
Acquisition of business (1,412) 0
Purchase of medical equipment (5,341) (12,162)
Purchase of property and equipment (427) (562)
Proceeds from sale of medical equipment, property and equipment 2,582 2,754
NET CASH USED IN INVESTING ACTIVITIES (4,598) (9,970)
FINANCING ACTIVITIES    
Principal payments on long-term debt (44,265) (40,415)
Cash proceeds from long-term debt 41,502 39,231
Debt issuance costs (230) 0
Common stock repurchased as part of share repurchase program (8,563) (981)
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (1,036) (625)
Cash proceeds from exercise of options and ESPP 336 381
NET CASH USED IN FINANCING ACTIVITIES (12,256) (2,409)
Net change in cash and cash equivalents 428 149
Cash and cash equivalents, beginning of period 527 231
Cash and cash equivalents, end of period $ 955 $ 380